FDA approves Amgen’s Repatha for heart attack and stroke prevention
In a significant advancement for cardiovascular disease management, Amgen's Repatha (evolocumab) has received approval from the U.S. Food and Drug Administration (FDA) to prevent heart ... Read More
Amgen’s Repatha proves effective in major cardiovascular outcomes study
Amgen Inc. has achieved a significant milestone with its cholesterol-lowering injection, Repatha (evolocumab), demonstrating a 20% reduction in heart attack and stroke risks among patients ... Read More